A researcher wants to test a teacher-focused intervention in schools. However, she worries that if she randomizes teachers within a school to receive the intervention or not, there may be contamination. She fears that teachers will talk to each other about the study, and that control group teachers will observe intervention teachers' behavior and model it, even though they were not randomized to receive the intervention. In response, the researcher decides to randomize different schools to receive the teacher intervention or no intervention.
John joins Amgen from Bristol-Myers Squibb (BMS), where he served as the global head of Clinical Development for marketed products as well as global clinical operations. Earlier roles at BMS included head of worldwide Medical and as a full development team lead in oncology. In these roles, John led a number of innovative changes to the company’s development and medical organizations and practices. He also served as chief medical officer, Europe, head of . Medical and vice president of Cardiovascular Medical. Prior to joining BMS, he was cardiovascular group leader at Pfizer, and was a member of the faculty staff at Kaiser Hospital in San Francisco.